“He didn’t say that thalassaemia might come up” — β-thalassaemia carriers’ experiences and attitudes
- 13 January 2013
- journal article
- Published by Springer Nature in Journal of Community Genetics
- Vol. 4 (2) , 223-232
Abstract
Tests for haemoglobinopathy carrier status are the commonest genetic screening tests undertaken internationally. Carrier screening for β-thalassaemia is not coordinated in Victoria, Australia, and is instead incorporated into routine practice where most women are screened antenatally, through a full blood examination (FBE). Little is known about how women are screened for β-thalassaemia in Australia as well as their attitudes towards the screening process. This study was conducted to explore carriers’ and carrier couples’ experiences of and attitudes towards β-thalassaemia screening in Australia. Semi-structured interviews with 26 recently pregnant female carriers and ten carrier couples of β-thalassaemia were carried out. Interviews were analysed using inductive content analysis. Unexpectedly, more than half of the women had been made aware of their carrier status prior to pregnancy, with FBEs carried out for numerous reasons other than thalassaemia screening. Most women did not recall being told about thalassaemia before notification of their carrier status and therefore did not make a decision about being screened. They were generally accepting for doctors to decide about testing; however, would have preferred to have been made aware of the screening test. Women also reported receiving insufficient information after being notified of their carrier status, leading to misconceptions and confusion. This genetic screening process, incorporated into routine care whereby informed decisions were not being made by patients, was apparently acceptable overall. Based on the results of this study, we make the following recommendations: (1) individuals should be made aware that they are being tested for thalassaemia at least before a specific thalassaemia diagnostic test is performed; (2) current understanding by known carriers of thalassaemia should be assessed and any misconceptions corrected; (3) written information should be provided to carriers; (4) referral of carrier couples to specialists in thalassaemia and genetics is strongly recommended; (5) the term ‘carrier of β-thalassaemia’ should be used rather than ‘thalassaemia minor’.Keywords
This publication has 26 references indexed in Scilit:
- Population‐based carrier screening for cystic fibrosis in Victoria: The first three years experienceAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2009
- Impact of internet use on health-related behaviors and the patient-physician relationship: a survey-based study and review.2008
- The qualitative content analysis processJournal of Advanced Nursing, 2008
- Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics eraBritish Journal of General Practice, 2008
- ACOG Practice Bulletin No. 78: Hemoglobinopathies in PregnancyObstetrics & Gynecology, 2007
- Three Approaches to Qualitative Content AnalysisQualitative Health Research, 2005
- Antenatal thalassaemia carrier testing: women's perceptions of 'information' and 'consent'Journal of Medical Screening, 2005
- Proposed international guidelines on ethical issues in medical genetics and genetic services (part I).2005
- Evaluation of a Tay‐Sachs Disease screening programClinical Genetics, 2003
- Strategies for Effective Patient Education Material DesignJournal of Cardiovascular Nursing, 1997